Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IBI3001 in Advanced Solid Tumors
NCT06349408Phase 1Recruiting
- Sponsor
- Fortvita Biologics
- Start
- Jan 2025
- Primary completion
- Dec 2026
- Modality
- Antibody-Drug Conjugates (ADCs), Engineered Antibody Formats, Monoclonal Antibodies
- Countries
- 3
01
Overview
Phase 1, open-label, single-arm trial of IBI3001 in solid tumor, sponsored by Fortvita Biologics. Primary endpoints: Adverse Events at 24 months, Clinically Significant Changes in Physical Examination Results at 24 months and 2 more. Started Jan 2025; status: recruiting.
02
Drugs
IBI3001
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT06349408.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06349408.